Hamm

• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 triple-negative early breast cancer
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• A Randomized, Placebo‐Controlled Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Adult Patients With Newly Di … Recruiting
  2023-507518-28-00 5 2022-09-13 Acute myeloid leukemia
• Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe … Recruiting
  2025-522585-72-00 6 2025-12-05 ulcerative colitis
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Recruiting
  2023-509861-19-01 4 2025-09-30 High-grade B-cell lymphoma (HGBL)
• A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration ( … Recruiting
  2023-510294-34-00 5 2025-06-12 small lymphocytic lymphoma (SLL)
• Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi … Recruiting
  2023-508076-11-00 5 2025-04-01 Colon cancer staged T3-4 and/or nodal positive by CT and/or MRI scan w
• 5% KOH solution vs placebo treatment of actinic keratosis with different treatment duration Recruiting
  2024-514277-21-00 5 2025-03-19 Actinic keratosis
• A clinical study comparing the efficacy and safety of a new cream containing ivermectin with the efficacy and safety of the originator produ … Recruiting
  2023-505897-13-00 5 2024-12-02 Papulopustular Rosacea
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• A trial to evaluate the efficacy and safety of oral controlled-ileocolonic-release nicotinamide (CICR-NAM) in patients with mild to moderate … Recruiting
  2024-510807-13-00 10 2024-09-12 ulcerative colitis
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (De … Recruiting
  2022-502811-12-00 5 2024-09-04 Actinic Keratosis (AK) of the Scalp and/or the Face.
• C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL … Recruiting
  2023-507871-23-00 5 2024-05-27 Relapsed/Refractory Multiple Myeloma
• Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 0.25 mg/g Tretinoin vs. the originator Acnatac(R) 10 m … Recruiting
  2023-504552-10-01 5 2024-05-14 Papulopustular acne
• Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting
  2022-501515-14-00 5 2023-09-29 Newly Diagnosed Multiple Myeloma (NDMM)
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 4 2023-07-13 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::ABL1 positive (Ph
• CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE … Recruiting
  2022-500764-35-00 6 2022-10-13 Patients with advanced HER2-negative, hormone receptor positive (HER2n
• Clinical study to compare the therapeutic effects of two ointments with the active substances clotrimazole and betamethasone dipropionate an … Recruiting
  2022-501415-14-00 5 2022-03-08 moderate to severely inflamed candidiasis of the skin
• Clinical study to compare two cutaneous ointments with the active substance methylprednisolone aceponate 0.1% and one cutaneous ointment wit … Recruiting
  2024-514548-10-01 3 2021-07-26 Mild to moderate atopic dermatitis
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+ … Ended recruitment
  2024-514458-61-01 4 2024-02-05 HER2+ early breast cancer
• AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare … Ended recruitment
  2024-511625-55-00 6 2022-11-30 EGFRmutated/T790M Mutation negative non-squamous NSCLC
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• ABP - Advancing Brigatinib Properties in anaplastic lymphoma kinase positive nonsmall cell lung cancer (ALK+ NSCLC) patients by deep phenoty … Ended recruitment
  2024-513947-94-00 4 2020-03-30 locally advanced (stage III) and not suitable for curative treatment,

Showing 1–24 of 36 trials